Evidence map›Paper›PMID 39497720›Full record

ArticleFrontiers in oncology2024

The potential role of next-generation sequencing in identifying

Xiao Xiao, Ren Xu, Jun Lu, Beibei Xin, Chenyang Wang, Kexin Zhu, Hao Zhang, Xinyu Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiao XiaoSchool of Physics, Changchun University of Science and Technology, Changchun, China.
Ren XuSchool of Physics, Changchun University of Science and Technology, Changchun, China.
Jun LuDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Beibei XinResearch & Development Department, Shanghai Rightongene Biotechnology Co., Ltd., Shanghai, China.
Chenyang WangResearch & Development Department, Shanghai Rightongene Biotechnology Co., Ltd., Shanghai, China.
Kexin ZhuResearch & Development Department, Shanghai Rightongene Biotechnology Co., Ltd., Shanghai, China.
Hao ZhangSchool of Life Science and Technology, Changchun University of Science and Technology, Changchun, China.
Xinyu ChenSchool of Physics, Changchun University of Science and Technology, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purposes: Osimertinib, one of the third-generation Methods: A total of 317 cancer tissue samples from 317 NSCLC patients at time of progression following osimertinib were submitted to NGS and only 96 tissues were tested by FISH simultaneously. With FISH results as gold standard, enumeration algorithm was applied to establish the optimal model for identifying Results: The optimal model for identifying Conclusions: NGS assay can achieve a high concordance with FISH in

Indexed as

fishMET amplificationnext generation sequencingnon-small cell lung cancerosimertinib resistance

Identifiers

PMID39497720
PMCPMC11532092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.